Robert Langreth is a senior reporter at Bloomberg News, specializing in science and health reporting. With a wide range of publications featuring his work, including Bloomberg Law, The Washington Post, and The Sydney Morning Herald, Langreth covers topics such as pharmaceutical companies, drug industry trends, and breakthroughs in medical research. His articles provide in-depth analysis and insights into the business and science behind the healthcare industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Robert Langreth's coverage predominantly focuses on the healthcare and pharmaceutical industry. He often cites data, press releases, and government announcements in his articles. To effectively reach out to him, consider providing fact-based insights supported by relevant data or official announcements related to the pharmaceutical industry.
Given his focus on specific companies and drug-related topics such as cancer drugs, weight loss drugs, Parkinson's cure, Alzheimer's research, etc., experts with direct knowledge of these areas would be valuable sources for Robert's articles.
While there is no specified geographic focus for Robert Langreth’s reporting based on the available information provided about his article titles and coverage attributes; however it seems that he has a global perspective when covering healthcare and pharmaceutical topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Lauerman, Robert Langreth, Myles Miller
The inscriptions loosely echo the book title Delay, Deny, Defend, which describes tactics allegedly used by insurers to deny claims. Law enforcement officials may look at whether it suggests a potential motive — anger against health insurers.
By: Robert Langreth, Myles Miller, John Lauerman
New York | The words “delay” and “depose” were written on a shell casing and a live round recovered in front of the New York Hilton Midtown, where
By: Robert Langreth
Hi, it’s Bob in windy New Jersey. The apparently targeted killing of a UnitedHealth Group executive has provoked vitriolic screeds against health insurers on social media. But first ...
Pfizer Inc. forecast 2025 revenue in line with analysts’ projections, a step toward fending off an activist investor’s claims that the drugmaker is being mismanaged.
Pfizer forecast 2025 sales and earnings in line with analysts' projections, a step toward fending off an activist investor's claims that the drugmaker is being mismanaged.
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
By: Nicholas Takahashi, Nicholas Gordon, Robert Langreth
By: Madison Muller, Robert Langreth
Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door for broader insurance coverage of the blockbuster medicine.
By: Madison Muller, Ike Swetlitz, Robert Langreth
Wegovy and Zepbound, the first-ever highly effective treatments for weight loss, were major advances. Why isn't progress faster?
By: Michelle F Davis, Robert Langreth, Gerry Smith
At the health-care industry’s annual confab this week in San Francisco, talk is likely to be more focused on what’s going on 3,000 miles away — at Mar-a-Lago.
(833) 317-6278 
